Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhıt; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Beköz, Hüseyin Saffet; Sevindik, Omur Gokmen; Toptaş, Tayfur; Koyun, Derya; Alkis, Nihan; Atesoglu, Elif Birtas

doi:10.1182/blood-2022-165385

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another real-world study, Atesoglu and colleagues analyzed the treatment responses of 43 patients receiving glofitamab via a CUP in Turkey. 25 The median number of prior lines of treatment in their cohort was four, which is slightly lower than that for the cohort in this study. The ORR and CR reported in the Atesoglu and colleagues study were 37% and 21%, respectively, with a median OS of 8.…”

Section: Discussioncontrasting

confidence: 59%

“…Thus, glofitamab may be an effective treatment for patients with DLBCL relapse after CAR T‐cell therapy. In another real‐world study, Atesoglu and colleagues analyzed the treatment responses of 43 patients receiving glofitamab via a CUP in Turkey 25 . The median number of prior lines of treatment in their cohort was four, which is slightly lower than that for the cohort in this study.…”

Section: Discussionmentioning

confidence: 61%

“…Given its promising trial results, it is important to understand how glofitamab might perform in an unselected patient population because limited real-world data exist on its clinical use. 24,25 In this study, we compiled efficacy and safety profiles of glofitamab as a salvage therapy for patients with DLBCL and other relevant aggressive subtypes of B-cell lymphomas in a real-world setting, specifically within a compassionate use program (CUP). Although the approved indication specifies patients with LBCL who have received two or more prior lines of systemic therapy, the CUP allowed treatment of patients who experienced relapse or failed to respond to a minimum of three prior systemic treatment regimens, and it also allowed treatment of patients with broader disease entities.…”

Section: Introductionmentioning

confidence: 99%

“…Given its promising trial results, it is important to understand how glofitamab might perform in an unselected patient population because limited real‐world data exist on its clinical use 24,25 . In this study, we compiled efficacy and safety profiles of glofitamab as a salvage therapy for patients with DLBCL and other relevant aggressive subtypes of B‐cell lymphomas in a real‐world setting, specifically within a compassionate use program (CUP).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan

Hsu,

Wu,

Kao

et al. 2024

Cancer

View full text Add to dashboard Cite

BackgroundGlofitamab is a bispecific antibody with promise for treating relapsed/refractory B‐cell lymphoma according to a phase 1/2 clinical trial. This study examined its real‐world effectiveness.MethodsThis was an investigator‐initiated, multicenter retrospective study including 34 patients who had relapsed/refractory B‐cell lymphomas after at least three prior lines of therapy and received glofitamab monotherapy in a compassionate use program in Taiwan between January 2021 and October 2022.ResultsAt a median follow‐up of 15.9 months, 56% of patients responded to glofitamab and 23% achieved complete remission. Response to the previous line of therapy significantly correlated with response to glofitamab (p = .020). Most responses were durable; only five out of the 19 responders had documented disease recurrence at the data cutoff date. The estimated progression‐free survival (PFS) was 3.2 months, and the estimated 1‐year PFS was 33% for the entire cohort. PFS was better for responders than nonresponders (median PFS, 16.9 vs. 1.8 months; 1‐year PFS, 60% vs. 0%). Forty‐three cytokine release syndrome (CRS) events were observed, three of which were grade 3; all were manageable without glofitamab discontinuation. No immune effector cell–associated neurotoxicity was reported. Among seven hepatitis B virus (HBV) carriers (six had antiviral prophylaxis) and 14 patients with remote HBV (four had antiviral prophylaxis), no HBV reactivation was observed.ConclusionsIn this real‐world cohort, glofitamab exhibited effectiveness comparable to trial results without excessive CRS or new safety issues. With appropriate prophylaxis, glofitamab‐treated patients with chronic or remote HBV infection are unlikely to experience virus reactivation.

show abstract

Section: Discussioncontrasting

confidence: 59%

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan

Hsu,

Wu,

Kao

et al. 2024

Cancer

View full text Add to dashboard Cite

show abstract

“…In another real-world study, Burhan Ferhanoglu [7] retrospectively analyzed 42 patients who received glofitamab via compassionate use in Turkey. The median number of prior therapeutic approaches for the patients was 4 (range 3-6).…”

Section: Glofitamab For R/r B Cell Lymphomamentioning

confidence: 99%

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting

Wang

Liu

2023

J Hematol Oncol

View full text Add to dashboard Cite

Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3 T-cell-engaging, bispecific antibody capable of recruiting T cells to tumor cells. We have summarized several of the latest reports on glofitamab use in B cell lymphoma therapy from the 2022 ASH Annual Meeting (ASH2022).

show abstract

The value of bispecific antibodies in relapsed and refractory DLBCL

Lewis,

Cheah

2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Cited by 6 publications

References 0 publications

Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan

Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting

The value of bispecific antibodies in relapsed and refractory DLBCL

Contact Info

Product

Resources

About